Backbone cyclic peptide, which mimics the nuclear localization signal of human immunodeficiency virus type 1 matrix protein, inhibits nuclear import and virus production in nondividing cells

Biochemistry
A FriedlerC Gilon

Abstract

Here, we describe an application of the backbone cyclic (BC) proteinomimetic approach to the design and the synthesis of a BC peptide which functionally mimics the nuclear localization signal (NLS) region of the human immunodeficiency virus type 1 matrix protein (HIV-1 MA). On the basis of the NMR structure of HIV-1 MA, a library of BC peptides was designed and screened for the ability to inhibit nuclear import of NLS-BSA in digitonin-permeabilized HeLa and Colo-205 cultured cells. The screening yielded a lead compound (IC50 = 3 microM) which was used for the design of a second library. This library led to the discovery of a highly potent BC peptide, designated BCvir, with an IC50 value of 35 nM. This inhibitory potency is compared to a value of 12 microM exhibited by the linear parent HIV-1 MA NLS peptide. BCvir also reduced HIV-1 production by 75% in infected nondividing cultured human T-cells and was relatively resistant to tryptic digestion. These properties make BCvir a potential candidate for the development of a novel class of antiviral drugs which will be based on blocking nuclear import of viral genomes.

References

Nov 25, 1994·Journal of Molecular Biology·M A MassiahW I Sundquist
May 1, 1997·The Journal of Peptide Research : Official Journal of the American Peptide Society·G BitanC Gilon

❮ Previous
Next ❯

Citations

May 24, 2007·Journal of Biomedical Science·Laurent ChaloinChristian Devaux
Apr 8, 2011·Journal of the American Society for Mass Spectrometry·Fuyu GuanJeffrey Rudy
Mar 21, 2002·Biochimica Et Biophysica Acta·Elana Hariton-GazalAbraham Loyter
Jun 6, 2003·Advanced Drug Delivery Reviews·Gary R Whittaker
Jun 16, 2001·Drug Discovery Today·K FrühP Ghazal
Nov 11, 2010·Protein Engineering, Design & Selection : PEDS·Assaf Friedler
Oct 14, 2000·Annual Review of Cell and Developmental Biology·G R WhittakerA Helenius
May 12, 2004·Biological Chemistry·Anja-Daniela EllenriederSusanne Modrow
Mar 24, 2011·Future Medicinal Chemistry·Hadar Benyamini, Assaf Friedler
Mar 11, 2005·Expert Review of Anti-infective Therapy·Omar Haffar, Michael Bukrinsky
Dec 6, 2008·Trends in Endocrinology and Metabolism : TEM·Eric N ChurchillDaria Mochly-Rosen
Mar 1, 2006·Molecular Plant Pathology·Alexander KrichevskyVitaly Citovsky
Jun 23, 2015·Biopolymers·Ana I Fernández-LlamazaresFernando Albericio
Oct 27, 2010·Bioorganic & Medicinal Chemistry·Zvi HayoukaAssaf Friedler
Aug 20, 2010·Biochimica Et Biophysica Acta·Aviad LevinMichael Bukrinsky
Sep 24, 1999·Journal of Molecular Biology·R KasherC Gilon
Aug 16, 2002·Antiviral Chemistry & Chemotherapy·Zeger DebyserMyriam Witvrouw
Aug 17, 2006·FEMS Microbiology Reviews·Reena GhildyalDavid A Jans
Jun 12, 2019·Cells·Tanner M TessierJoe S Mymryk
Apr 20, 2014·Frontiers in Microbiology·Carolin A GuenzelSerge Benichou
Oct 7, 2009·Pharmacological Reviews·Mirna N Chahine, Grant N Pierce
Apr 15, 2000·The Journal of Biological Chemistry·A FriedlerC Gilon
May 15, 2002·The Journal of Peptide Research : Official Journal of the American Peptide Society·S GazalC Gilon
May 5, 2004·The Journal of Biological Chemistry·Vitaly CitovskyAbraham Loyter
May 2, 2002·Journal of the American Chemical Society·Songpon Deechongkit, Jeffery W Kelly
Jul 5, 2003·Organic Letters·Seung Bum ParkRobert F Standaert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.